Table 2 Characteristics of the included trials and particiants

Spence et al. [11] 2018

I 28 (1.5%) 12 (2.4%)

II 43 (2.3%) 20 (4.0%)

III 59 (3.1%) 16 (3.2%)

IV 119 (6.3%) 16 (3.2%)

Missing 1646 (86.9%)

432 (87.1%)

Low-dose aspirin (75 mg) use

182, 365, 548

and 730 tablets

Unknown

not associated with increased survival in sophageal or gastric cancer

Spence et al. [11] 2018

Unknown

Low-dose aspirin (75 mg) use

182, 365, 548

and 730 tablets

Unknown

not associated with increased survival in sophageal or gastric cancer

Frouws et al. [7] 2017

Unknown

Nonusers were defined as patients who received for less than 30 days or never used aspirin.

Unknown

Unknown

increased survival

in cancers

Macfarlane et al. [13] 2015

Unknown

Unknown

Unknown

Unknown

improved survival was observed

Spence et al. [11] 2018

I 34 (1.6%) 10 (1.8%)

II 69 (3.2%) 28 (5.0%)

III 183 (8.4%) 47 (8.4%)

IV 132 (6.1%) 23 (4.1%)

Unknown 1756 (80.8%)

451 (80.7%)

Low-dose aspirin (75 mg) use

182, 365, 548

and 730 tablets

Unknown

not associated with increased survival in sophageal or gastric cancer

Spence et al. [11] 2018

Unknown

Low-dose aspirin (75 mg) use

182, 365, 548

and 730 tablets

Unknown

not associated with increased survival in sophageal or gastric cancer

Frouws et al. [7] 2017

Unknown

Nonusers were defined as patients who received for less than 30 days or never used aspirin.

Unknown

Unknown

increased survival in cancers

Chan et al. [17] 2009

I 228 (32%) 193 (35%)

II 260 (36%) 186 (33%)

III 231 (32%) 181 (32%)

I 218 (30%) 203 (37%)

II265 (36%) 181 (33%)

III 247 (34%) 165 (30%)

used aspirin 2 or more timesper week

Unknown

Headache, arthritis and other musculoskeletal pain, cardiovascular disease

associated with lower risk of colorectal cancer–specific and overall mortality

Liao et all [20]. 2012

I 112 (24%) 102 (30%)

II 159 (34%) 87 (26%)

III 128 (27%) 99 (29%)

IV 31 (7%) 18 (5%)

Unknown 36 (8%) 31 (9%)

I 19 (20%) 27 (41%)

II 36 (38%) 19 (29%)

III 23 (24%) 14 (21%)

IV 12 (13%) 3 (5%)

Unknown 5 (5%) 3 (5%)

as regular use of aspirin duringmost weeks

Unknown

Headache, arthritis and other musculoskeletal pain, cardiovascular disease

associated with longer survival among patients with mutated-PIK3CA colorectal cancer

Walker et al. [20] 2012

Unknown

a repeat prescription (> 2) within the period

a fixed period of 1 year post-diagnosis

Unknown

have a potential as anti-neoplastics in

diagnosed colorectal cancer

Domingo et al. [18] 2013

II 332 (48.7%) 57 (51.4%)

III 349 (51.2%) (54 48.6%)

II 46 (51.1%) 8 (57.1%)

III 44 (48.9%) 6 (42.9%)

taking regularlow-dose aspirin at random assignment or who started during follow-up

Unknown

adjuvant setting of colorectal cancer:

support the prospective evaluation of adjuvant low-dose aspirin in

patients with tumor PIK3CA mutation

McCowan et al. [19] 2013

Unknown

28 tablets at one per day gave coverage for that prescription of 28 days.

date of the first prescription post-diagnosis to the end of coverage of the last prescription

Unknown

use post-diagnosis of colorectal cancer may reduce both all cause and colorectal cancer specific mortality

Kothari et al. [21] 2015

I 6(4%) 2(4%)

II 50(37%) 16(33%)

III 45(33%) 22(45%)

IV 35(26%) 9(18%)

at least 75 mg of aspirin daily at the time of CRC diagnosis

Unknown

Unknown

significant improvements in survival in PIK3CA-mutated CRC patients

Reimers et al. [5] 2014

I 95 (13.8%) 38(21.2%)

II 218 (31.9%) 69(38.5%)

III 219 (32.0%) 57(31.8%)

IV149(21.8%) 15(0.8%)

Unknown 3 (0.4%)

given a prescription for aspirin for 14 days or more after a colon cancerdiagnosis

Unknown

Unknown

Increased PTGS2 expression or the presence of mutated PIK3CA did not predict benefit from aspirin

Cardwell et al. [16] 2014

I 65 (4.2%)

II 283 (18.2%)

III 565 (36.2%)

IV 187 (12.0%)

Missing 459 (29.4%)

low dose if 75 mg(0.3% of prescriptions after cancer diagnosis were 25 mg,98.5% were 75 mg, and 1.2% were 300 mg).

Duration of use was determined from quantity of tablets.

Unknown

low-dose aspirin usage after diagnosis of colorectal cancer did not increase survival time.

Bains et al. [6] 2016

I 3600 (21.9%) 1631 (27.7%)

II 4840 (29.4%) 2112 (35.9%)

III 4829 (29.3%) 1581 (26.8%)

IV 3188 (19.4%) 565 (9.6%)

three or more prescriptions of aspirin starting from 30 days after the diagnosis of CRC

Aspirin prescriptions lasted 3 months at a time (100-tablet packets, one tablet once per day),

Unknown

Aspirin use after the diagnosis of CRC is independently associated with improved CSS and OS.

Frouws et al. [7] 2017

Unknown

Nonusers were defined as patients who received for less than 30 days or never used aspirin.

Unknown

Unknown

increased survival in cancers

Newcomb et al. [14] 2017

I 326 (30%) 311 (36%)

II 391 (36%) 259 (30%)

III 263 (24%) 225 (26%)

IV 106 (10%) 61 7 (%)

Unknown 311,166

using the medications at least twice per week for more than 1 month

Pre-diagnostic use 1 year before diagnosis /post-diagnostic use between baseline

and the 5-year follow-up interview

Unknown

regular use of NSAIDs after CRC diagnosis was significantly associated with improved survival in individuals with KRAS wild-type tumors

Gray et al. [23] 2018

A 1683(27.0%) 597(27.8%)

B 2340(37.5%) 851(39.6%)

C 2218(35.5%) 702(32.7%)

Low-dose (75 mg) aspirin exposure was identified from dispensing

records within this database

users after a lag of 6 months after their first aspirin

prescription

Unknown

either before or after diagnosis, did not prolong survival in this population-based CRC cohort.

Joseph et al. [24] 2019

Unknown

no less than 80 mg per day

at least a month

Unknown

lowers risk of both CRC-related mortality and overall mortality

Zell et al. [15] 2009

Unknown

taken aspirin regularly at least once a week

the total duration of use in number of years (< 1, 1, 2, 3–4, 5–9, or 10).

Unknown

NSAIDs are associated with decreased mortality among female CRC patients

Din et al. [4] 2010

Unknown

reported intake of aspirin

Unknown

Unknown

NSAID use prior to CRC

diagnosis does not influence survival of colorectal cancer

Coghill et al. [14] 2011

Unknown

at least twice per week for 1 month

first, 0–6 months; second, 6 monthse2.5 years; third, 2.5–7 years; fourth, > 7 years).

Unknown

regular use of

NSAIDs prior to diagnosis is associated with improved

colorectal cancer survival